NASDAQ:ABVX Abivax (ABVX) Stock Price, News & Analysis $7.97 +0.21 (+2.71%) As of 07/3/2025 01:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Abivax Stock (NASDAQ:ABVX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Abivax alerts:Sign Up Key Stats Today's Range$7.65▼$8.0650-Day Range$5.67▼$8.1952-Week Range$4.77▼$14.16Volume374,623 shsAverage Volume164,865 shsMarket Capitalization$505.70 millionP/E RatioN/ADividend YieldN/APrice Target$31.00Consensus RatingBuy Company Overview ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France. Read More Abivax Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreABVX MarketRank™: Abivax scored higher than 48% of companies evaluated by MarketBeat, and ranked 554th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAbivax has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAbivax has only been the subject of 1 research reports in the past 90 days.Read more about Abivax's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Abivax are expected to grow in the coming year, from ($2.83) to ($2.57) per share.Price to Book Value per Share RatioAbivax has a P/B Ratio of 11.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Abivax's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.27% of the float of Abivax has been sold short.Short Interest Ratio / Days to CoverAbivax has a short interest ratio ("days to cover") of 6.7.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAbivax does not currently pay a dividend.Dividend GrowthAbivax does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.27% of the float of Abivax has been sold short.Short Interest Ratio / Days to CoverAbivax has a short interest ratio ("days to cover") of 6.7.Change versus previous month News and Social Media2.9 / 5News SentimentN/A News SentimentAbivax has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Abivax this week, compared to 2 articles on an average week.Search Interest3 people have searched for ABVX on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Abivax insiders have not sold or bought any company stock.Percentage Held by Institutions47.91% of the stock of Abivax is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Abivax's insider trading history. Receive ABVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abivax and its competitors with MarketBeat's FREE daily newsletter. Email Address ABVX Stock News HeadlinesPositive Outlook for Abivax SA: Anticipated Success of Obefazimod in Ulcerative Colitis TreatmentJuly 4 at 6:16 AM | tipranks.comBuy Rating Justified for Abivax SA: Promising Efficacy of Obefazimod in Ulcerative Colitis and Crohn’s DiseaseJune 24, 2025 | tipranks.comA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. | Porter & Company (Ad)Abivax Announces Results of its June 6, 2025 Annual General MeetingJune 11, 2025 | globenewswire.comAbivax Presents First Quarter 2025 Financial ResultsJune 2, 2025 | globenewswire.comAbivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative ColitisApril 29, 2025 | globenewswire.comAbivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving MilestonesApril 22, 2025 | globenewswire.comAbivax Announces Appointment of Dominik Höchli, MD to Board of DirectorsApril 22, 2025 | globenewswire.comSee More Headlines ABVX Stock Analysis - Frequently Asked Questions How have ABVX shares performed this year? Abivax's stock was trading at $7.32 at the beginning of the year. Since then, ABVX shares have increased by 8.9% and is now trading at $7.97. When did Abivax IPO? Abivax (ABVX) raised $217 million in an initial public offering on Friday, October 20th 2023. The company issued 18,699,460 shares at $11.60 per share. How do I buy shares of Abivax? Shares of ABVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Abivax own? Based on aggregate information from My MarketBeat watchlists, some other companies that Abivax investors own include Adverum Biotechnologies (ADVM), APi Group (APG), Avino Silver & Gold Mines (ASM), Boot Barn (BOOT), G1 Therapeutics (GTHX), Howard Hughes (HHH) and KT (KT). Company Calendar Today7/05/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ABVX Previous SymbolNASDAQ:ABVX CIK1956827 Webwww.abivax.com Phone33-1-53-83-09-63FaxN/AEmployees61Year FoundedN/APrice Target and Rating Average Stock Price Target$31.00 High Stock Price Target$48.00 Low Stock Price Target$12.00 Potential Upside/Downside+289.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio1.29 Current Ratio1.25 Quick Ratio1.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.69 per share Price / Book11.55Miscellaneous Outstanding Shares63,450,000Free FloatN/AMarket Cap$505.70 million OptionableNot Optionable Beta0.33 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:ABVX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abivax SA Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Abivax With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.